Kyoto, Japan and Marcy l'Etoile, France - 21 May 2010 - Shimadzu and bioMérieux announce today that they have entered into a partnership to commercialise a mass spectrometry system for bacterial identification in microbiology laboratories. bioMérieux will work with Shimadzu and t
A world leader in the field of in vitro diagnostics for 45 years, bioMérieux provides diagnostic solutions (reagents, instruments and software) that determine the source of disease and contamination to improve patient health and ensure consumer safety.
Our company is focused on diagnosing infectious diseases – in particular, sepsis, healthcare-associated infection (HAI), tuberculosis, AIDS and hepatitis. We also offer a range of tests that deliver high medical value results for cancer screening / monitoring and cardiovascular emergencies.
Diagnostic tools for HAI prevention and control
bioMérieux focuses on three key areas in infection control (prevention, surveillance and intervention). We work closely with microbiologists and physicians to provide the most relevant diagnostic tools to help prevent and control HAI. Our unique offer helps improve healthcare quality and patient safety, while actively contributing to reducing the cost and number of HAI cases.
- A unique combination of culture and molecular testing for a complete MRSA screening solution: chromID MRSA and NucliSENS EasyQ® MRSA*
- An automated test for detection of Clostridium difficile toxins A and B: VIDAS® C. difficile toxin A&B
- Epidemiology / surveillance software: VigiGUARD®** and ICNet®***
- Reference technique for manual antibiotic resistance testing: Etest®
- Automated identification and antimicrobial susceptibility testing: VITEK® 2
- Genotyping of microbial strains: DiversiLab®
Emergency diagnostics panel for ER and critical care units
The VIDAS emergency diagnostics panel covers early diagnosis of acute coronary syndrome (ACS), heart failure, deep vein thrombosis (DVT) and pulmonary embolism (PE), and early management of severe bacterial infections.
This panel is particularly adapted for the rapid differential diagnosis of patients with common symptoms such as chest pain, shortness-of-breath (SOB), fever and cough.
- VIDAS D-Dimer Exclusion: the referenced non-invasive test for safe, reliable exclusion of DVT/PE
- VIDAS NT-proBNP: for early diagnosis and risk stratification of heart failure
- VIDAS Troponin I Ultra: the biomarker of choice for myocardial damage and diagnosis of ACS
- VIDAS B.R.A.H.M.S. PCT: for early detection and monitoring of sepsis and bacterial infection
With a turnaround time of 20min-35min, these reliable tests help physicians determine the adapted course of action fast for improved patient management.
Early biomarker for the management of severe bacterial infections / sepsis
Early recognition and timely initiation of appropriate therapy is key to improving the outcome of patients with sepsis.
Procalcitonin (PCT) – a biomarker which is specifically increased during bacterial infection and sepsis – is increasingly being recognised as a useful diagnostic tool.
VIDAS B.R.A.H.M.S PCT is an innovative, automated assay for sensitive and specific measurement of procalcitonin levels. It is indicated for use in the early detection of sepsis and severe bacterial infections, and an aid to assess risk of progression to severe sepsis and septic shock.
This test provides results in just 20min and runs on bioMérieux’s VIDAS and mini VIDAS systems, which are fully adapted to emergency / critical care settings.
Full Microbiology Lab Automation
bioMérieux is leading the way in delivering Full Microbiology Lab Automation to microbiology labs worldwide. This avant-garde approach streamlines laboratory workflow and boosts efficiency through a complete range of automated platforms for front-end media processing, blood culture, identification, antimicrobial susceptibility testing and microbial strain typing.
- Inoculation of plated media: PREVI Isola
- Automated staining of sample slides: PREVI Color Gram
- Urinary screening (detection of bacteria and particles): UF-1000i/UF500i range
- Blood culture: BacT/ALERT®
- Identification and antimicrobial susceptibility testing: VITEK 2
- Genotyping of microbial strains: DiversiLab
*available end of 2009
**not available in US
***available in US only
Marcy l'Etoile (France) and Cambridge, Massachusetts (US) - 21 April 2010 - Exclusive agreement to bring state-of-the-art genome sequencing technology to the in vitro diagnostics market. bioMérieux takes equity stake in Knome. bioMérieux and Knome announced today
Philips and bioMérieux Announce Partnership to Develop and Market Next-Generation Handheld Diagnostic Solutions for Point-of-Care
Fully automated handheld diagnostic test devices designed to improve diagnosis and disease management in critical care settings within hospitals. Amsterdam, The Netherlands, Marcy l'Etoile, France – 7 January 2010 - Royal Philips Electronics and bioMérieux today annou
Marcy l'Etoile, France, 12 November 2009 - A world leader in the field of in vitro diagnostics, bioMérieux has adapted its molecular NucliSENS EasyQ® Influenza A/B test to include the new A(H1N1) strain. In line with its long-standing commitment to the fight agai
Methicillin-resistant Staphylococcus aureus (MRSA) is the most prevalent multi-drug resistant bacteria and a growing threat to health. Marcy l'Etoile, France, 6 November 2009 - bioMérieux, a world leader in the field of in vitro diagnostics, today launched Nucl
chromID MRSA Launched in US – bioMérieux Adds Methicillin-Resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal
Chromogenic media provides cost-effective MRSA identification for hospitals and labs. Durham, NC (US), 28 October 2009 – bioMérieux, a world leader in the field of in vitro diagnostics, today announced the US launch of chromID MRSA, a simple and cost-effe
- Newly evolved enzymes make some bacteria resistant to all common antibiotics - Healthcare workers slow to receive flu vaccines - Countries not doing enough to combat 'superbugs' About 7 million healthcare-associated infections (HAIs) in the US and Europe each year
bioMérieux, a world leader in the field of in vitro diagnostics (IVD), offers the most comprehensive diagnostic solution on the market to help hospitals and healthcare facilities fight healthcare-associated infection (HAI). HAI is now recognised worldwide as a major public h